\
&
Contact us
Starts in 1 week from now
LocationArlon
This contact day is designed for companies active in unmanned systems, defence vehicle components or space applications. It offers selected participants the chance to learn how to become an NSPA supplier, get information on NATO procurement programmes, and speak directly with NSPA buyers.
The event is organised by Flanders Investment & Trade together with AWEX and hub.brussels.
The programme focuses on three areas:
NSPA supports 32 NATO member states and works with more than 60,000 companies worldwide across procurement programmes covering equipment, operational support and lifecycle management.
Participation is based on selection. Companies can apply through the registration form, and those selected by NSPA are expected to receive the full practical information and programme afterwards. A discount code for an overnight stay at the hotel at a reduced rate is also expected to be shared after registration.
The participation fee is €250 for the first participant and €100 for the second participant. Companies that are new to Flanders Investment & Trade may receive a 35% discount. The application deadline is 19 March 2026.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.